PET Scan With a Radiotracer to Detect Newly Diagnosed Prostate Cancer
Compares a PSMA-targeted PET scan with MRI to detect untreated prostate cancer.
Plain-language title generated from the registry record
Registry title: 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
Key facts
- Where
- Fuzhou, ChinaSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07209878, who can take part
Where in China
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical UniversityFuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Fujian Medical University
- Trial code
- NCT07209878
- Record updated
- 7 October 2025
- Original description
68Ga-PSMA-11 is a widely used radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-PSMA-11 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).Read full original descriptionShow less
68Ga-PSMA-11 PET Imaging in the Diagnostic Study of Newly Diagnosed, Untreated Prostate Cancer, With a Head-to-head Comparison to mpMRI
68Ga-PSMA-11 is a widely used radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-PSMA-11 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).
Inclusion: Biopsy-confirmed adenocarcinoma of the prostate; No anti-tumor treatment received prior to the PET imaging; Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements; Radical prostatectomy scheduled within 28 days after PET imaging.
Exclusion: Patients with other malignant tumors; Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.